Order Article Reprints

Sugino F, Nakane K, Kawase M, Ueda S, Tomioka M, Takeuchi Y, Tomioka-Inagawa R, Yamada T, Namiki S, Kumada N, et al. Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer. Life. 2023; 13(5):1072. https://doi.org/10.3390/life13051072

Sugino, Fumiya, Keita Nakane, Makoto Kawase, Shota Ueda, Masayuki Tomioka, Yasumichi Takeuchi, Risa Tomioka-Inagawa, Toyohiro Yamada, Sanae Namiki, Naotaka Kumada, and et al. 2023. "Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer" Life 13, no. 5: 1072. https://doi.org/10.3390/life13051072

Sugino, F., Nakane, K., Kawase, M., Ueda, S., Tomioka, M., Takeuchi, Y., Tomioka-Inagawa, R., Yamada, T., Namiki, S., Kumada, N., Takeuchi, S., Kawase, K., Kato, D., Takai, M., Iinuma, K., Tobisawa, Y., & Koie, T. (2023). Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer. Life, 13(5), 1072. https://doi.org/10.3390/life13051072